Preview

Experimental and Clinical Gastroenterology

Advanced search

The need for individual selection of probiotics containing lactobacilli and enterococci to increase the effectiveness of therapy for campylobacteriosis

https://doi.org/10.31146/1682-8658-ecg-186-2-88-93

Abstract

The article highlights the problem of improving the rational treatment of campylobacteriosis. Probiotics are present in treatment regimens along with antibiotics, which have the advantage that they do not violate intestinal microbiocenosis and provide the ability to correct dysbiotic conditions. As well as antimicrobial agents, probiotics have different effects on the growth of pathogenic microorganisms. Campylobacter spp. probiotics in the in vitro system. The article studies the anticampylobacter activity of probiotic cultures of Enterococcus faecium L3, Lactobacillus plantarum 8 R-A3, a mixture of Lactobacillus acidophilus and Saccharomyces boulardii by two-layer agar and droplet method. Analysis of the antagonistic activity of chemically synthesized bacteriocins. The high sensitivity of Campylobacter spp was presented. to probiotics having lactobacilli and enterococci, as well as their metabolites (including bacteriocins). The strain-specific activity of probiotics and its dependence on their ability to produce bacteriocins were found. The results and data of other researchers indicate the need for individual selection of probiotics for the treatment of campylobacteriosis, the feasibility of analyzing the bacteriocinogenicity of the strains and testing their effect on the growth of clinical isolates.

About the Authors

K. D. Ermolenko
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation


N. P. Boldyreva
Saint-Petersburg State University
Russian Federation


E. A. Martens
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation


L. I. Zhelezova
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation


S. V. Sidorenko
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation


A. N. Suvorov
Saint-Petersburg State University; Institute of Experimental Medicine (FSBSI “IEM”)
Russian Federation


E. I. Ermolenko
Saint-Petersburg State University; Institute of Experimental Medicine (FSBSI “IEM”)
Russian Federation


References

1. Same R. G., Tamma P. D. Campylobacter infections in children. Pediatrics in review. 2018, Vol. 39, no. 11, pp. 533-541.

2. Kaakoush N.O., Castaño-Rodríguez N., Mitchell H. M., Man S. M. Global epidemiology of Campylobacter infection. Clinical microbiology reviews, 2015, Vol. 28, no. 3, pp. 687-720.

3. Dasti J. I., Tareen A. M., Lugert R., Zautner A. E., Groß, U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. International Journal of Medical Microbiology, 2010, Vol. 300, no. 4, pp. 205-211.

4. Endtz H. P., Ruijs G. J., van Klingeren B., Jansen W. H., van der Reyden T., Mouton R. P. (1991).Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. Journal of Antimicrobial Chemotherapy, 1991, Vol. 27, no. 2, pp. 199-208.

5. Acheson D., Allos B. M. Campylobacter jejuni infections: update on emerging issues and trends. Clinical infectious diseases, 2001, Vol. 32, no. 8, pp. 1201-1206.

6. Schönberg-Norio D., Mattila L., Lauhio A., Katila M. L., Kaukoranta S. S., Koskela M., Rautelin, H. Patient-reported complications associated with Campylobacter jejuni infection. Epidemiology & Infection, 2010, Vol. 138, no. 7, pp. 1004-1011.

7. Mohan V. The role of probiotics in the inhibition of Campylobacter jejuni colonization and virulence attenuation. European Journal of Clinical Microbiology & Infectious Diseases, 2015, Vol. 34, no. 8, pp. 1503-1513.

8. Usenko D.V., Gorelov A. V. Modern principles of antibacterial therapy of acute intestinal infections in children. Pharmateca, 2007, no. 5, pp. 75-80. (In Russ.)@@ Усенко Д. В., Горелов А. В. Современные принципы антибактериальной терапии острых кишечных инфекций у детей. Фарматека, 2007, no. 5, С. 75-80.

9. Shane A. L., Mody R. K., Crump J. A., Tarr P. I., Steiner T. S., Kotloff K., Cantey J. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clinical Infectious Diseases, 2017, Vol. 65, no. 12, P. e45-e80.

10. Guarino A. Foreword: ESPGHAN/ESPID evidence-based guidelines for the management of acute gastroenteritis in children in Europe. Journal of pediatric gastroenterology and nutrition, 2008, Vol. 46, vii-viii P.

11. Ternhag A., Asikainen T., Giesecke J., EkdahlK. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clinical Infectious Diseases, 2007, Vol. 44, no. 5, pp. 696-700.

12. Ebrahimnezhad H., Barzegar L., Esmaeili D. Antibacterial Effects of Compound Bifilact on E. coli and Campylobacter jejuni. Medical Laboratory Journal, 2020, Vol. 14, no. 1, pp. 15-19.

13. Tang Y., Fang L., Xu C., Zhang Q. Antibiotic resistance trends and mechanisms in the foodborne pathogen, Campylobacter. Animal health research re views, 2017, Vol. 18, no. 2, pp. 87-98.

14. Bratz K., Gölz, G., Janczyk, P., Nöckler, K., Alter, T. Analysis of in vitro and in vivo effects of probiotics against Campylobacter spp. Berl. Münc. Tierärztl. Wochenschr, 2015, Vol. 128, pp. 155-162.

15. Wang, G., Zhao, Y., Tian, F., et al. Screening of adhesive lactobacilli with antagonistic activity against Campylobacter jejuni. Food Control, 2014, Vol. 44, pp. 49-57.

16. Nishiyama, K., Seto, Y., Yoshioka, K., Kakuda, T., Takai, S., Yamamoto, Y., & Mukai, T. Lactobacillus gasseri SBT2055 reduces infection by and colonization of Campylobacter jejuni. PLoS One, 2014, Vol. 9, no. 9.

17. Campana, R., Federici, S., Ciandrini, E., Baffone, W. Antagonistic activity of Lactobacillus acidophilus ATCC 4356 on the growth and adhesion/invasion characteristics of human Campylobacter jejuni. Current microbiology, 2012, Vol. 64, no. 4, pp. 371-378.

18. Neal-McKinney, J. M., Lu, X., Duong, T., Larson, C. L., Call, D. R., Shah, D. H., Konkel, M. E. Production of organic acids by probiotic lactobacilli can be used to reduce pathogen load in poultry. PloS one, 2012, Vol. 7, no. 9, e43928 P.

19. Chaveerach P., Lipman L. J. A., Van Knapen F. Antagonistic activities of several bacteria on in vitro growth of 10 strains of Campylobacter jejuni/coli. International Journal of Food Microbiology, 2004, Vol. 90, no. 1, pp. 43-50.

20. Saint-Cyr, M. J., Haddad, N., Taminiau, B., Poezevara, T., Quesne, S., Amelot, M., Guyard-Nicodeme, M. Use of the potential probiotic strain Lactobacillus salivarius SMXD51 to control Campylobacter jejuni in broilers. International journal of food microbiology, 2017, Vol. 247, pp. 9-17.

21. Ermolenko E.I., Isakov V. A., Zhdan-Pushkina S. Kh., Tets V. V. Quantitative characteristics of the antagonistic activity of lactobacilli. Journal of Microbiology, Pidemiology and Immunology. 2004, No. 5, pp. 94-98. (In Russ.)@@ Ермоленко Е. И., Исаков В. А., Ждан-Пушкина С.Х., Тец В. В. Количественная характеристика антагонистической активности лактобацилл. Журнал микробиологии, пидемиологии и иммунологии. - 2004. - № 5. - C. 94-98.


Review

For citations:


Ermolenko K.D., Boldyreva N.P., Martens E.A., Zhelezova L.I., Sidorenko S.V., Suvorov A.N., Ermolenko E.I. The need for individual selection of probiotics containing lactobacilli and enterococci to increase the effectiveness of therapy for campylobacteriosis. Experimental and Clinical Gastroenterology. 2021;(2):88-93. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-186-2-88-93

Views: 538


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)